NASDAQ: PDSB · Life Sciences · 8 alerts · CIK 1472091
Share price
$0.9241Close, Nov 16
Market cap
$97M
Shares outstanding
105.01MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All PDS Biotechnology Corp filings on SEC EDGAR ↗
PDS Biotechnology reported third quarter 2026 financial results, highlighting a strategic shift to PDS0301 as its lead development program. The company also noted the initial closing of a $22.3 million PIPE financing led by Nant Capital and the appointment of several new board members, including Dr. Patrick Soon-Shiong.
“During our third quarter, we continued to execute our strategic prioritization of PDS0301, our investigational tumor-targeted IL-12 immunocytokine, as our lead development program. We believe the ongoing clinical trials of PDS0301 at the NCI, along with those of our cancer vaccine platform, support our view that targeted T cell immunotherapy has the potential to change how solid tumors are treated.”
Frank Bedu-Addo, PhD, President and Chief Executive Officer
NantWorks exercised outstanding common stock warrants to purchase 17,699,115 shares of PDS Biotechnology at an exercise price of $0.22 per share. The transaction generated approximately $3.9 million in gross proceeds for the company. PDS Biotech intends to use the funds to advance its PDS0301 program toward a Phase 3 trial in metastatic colorectal cancer and for general corporate purposes.
PDS Biotechnology updated its corporate presentation deck for October 2026, providing an overview of its oncology drug development programs. The presentation includes updates on its Versamune-based product candidates, including PDS0101 and PDS0301, and discusses the company's research and development strategy.
PDS Biotechnology announced a significant board reconstitution with the immediate resignation of four directors (Kamil Ali-Jackson, Stephen Glover, Gregory Freitag, and Otis Brawley) and the appointment of three new directors: Deborah A. Ramsdell, John A. Dawson CBE, and Bruce Wendel. The new appointees bring extensive experience in drug development, commercialization, and regulatory affairs as the company prepares for Phase 3 trials of PDS0301.